Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Nuvation BioNUVB +3.86%32 Days Payable is 166.31 as of Jun. 2026, which is 37% below its 10-year median of 265.64. GuruFocus rates NUVB with a GF Score™ of 32/100. The stock has 3 warning signs investors should review. Among 702 Biotechnology companies, Nuvation Bio ranks better than 70.94% on this metric.
The historical data trend for Nuvation Bio's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Nuvation Bio's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nuvation Bio Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Nuvation Bio's Days Payable distribution charts can be found below:
* The bar in red indicates where Nuvation Bio's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Nuvation Bio's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nuvation Bio (NUVB) has a Days Payable of 166.31 as of Jun. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Nuvation Bio and its competitors. This is 37% below median its historical median of 265.64. Over the past decade, Nuvation Bio's Days Payable has ranged from 220.63 to 310.65. According to the industry distribution chart, Nuvation Bio ranks #204 out of 702 companies in the Biotechnology industry, placing it in the top 29.1%.
Is Nuvation Bio's Days Payable too high?
Nuvation Bio's current Days Payable of 166.31 is 37% below median its 10-year median of 265.64. Over the past 10 years, this metric has ranged from a low of 220.63 to a high of 310.65. The Biotechnology industry median Days Payable is 110.69. Nuvation Bio's value of 166.31 is 50.2% above this industry median. Based on the distribution chart, Nuvation Bio ranks #204 out of 702 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Nuvation Bio has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Nuvation Bio's Days Payable compare to IOVA and SLS?
According to the Biotechnology industry distribution chart, Nuvation Bio ranks #204 out of 702 companies for Days Payable. This puts Nuvation Bio in the upper half of its industry. The industry median Days Payable is 110.69. Nuvation Bio's value of 166.31 is 50.2% above this benchmark. Historically, Nuvation Bio's own Days Payable has ranged from 220.63 to 310.65 over the past decade. While the company's 10-year median is 265.64 vs. the industry median of 110.69, Nuvation Bio has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 110.69, based on 702 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Nuvation Bio's current Days Payable of 166.31 is 50.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Nuvation Bio and its competitors. For the Biotechnology industry, the median Days Payable is 110.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nuvation Bio's current Days Payable is 166.31, which is 37% below median its own 10-year median of 265.64. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nuvation Bio stock overvalued right now?
Nuvation Bio (NUVB) has a current Days Payable of 166.31. The current Days Payable is 166.31, which is 37% below median its 10-year median of 265.64 and 50.2% above the Biotechnology industry median of 110.69. Nuvation Bio's overall GF Score™ is 32/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Nuvation Bio (NUVB), the current Days Payable is 166.31 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in different stages of development. The Company generates revenue from out-licensing collaborative agreements, including product revenue, upfront license fees, royalty revenue, and research and development services revenue. The Company generates the majority of its revenue from Japan.
32GF Score
Get the complete analysis for NUVB
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NUVB has been successfully added to your 
